XML 60 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
Quarterly Financial Information (Unaudited)
 12 Months Ended
Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Information (Unaudited)
Quarterly Financial Information (Unaudited)
The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2014 and 2013 (unaudited):
 
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
December 31,
2014

September 30,
2014

June 30,
2014

March 31,
2014
Consolidated Statements of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
Revenue under collaborative research and development arrangements
$
1,758,108

 
$
1,114,952

 
$
3,107,781

 
$
1,435,727

Revenue under collaborative research and development arrangements with affiliated entity
112,500

 
112,500

 
137,500

 
116,964

Grants and miscellaneous revenue
586,500

 
612,901

 
556,381

 
804,952

Total revenues
2,457,108

 
1,840,353

 
3,801,662

 
2,357,643

Operating Expenses:
 
 
 
 
 
 
 
Research and development
9,244,473

 
7,017,805

 
9,607,281

 
8,225,480

General and administrative
4,224,429

 
3,153,714

 
4,347,327

 
4,132,218

Total operating expenses
13,468,902

 
10,171,519

 
13,954,608

 
12,357,698

Loss from operations
(11,011,794
)
 
(8,331,166
)
 
(10,152,946
)
 
(10,000,055
)
Interest and other income, net
113,212

 
97,174

 
68,999

 
52,076

Change in fair value of common stock warrants
143,659

 
(113,980
)
 
824,390

 
(505,926
)
Gain (Loss) from investment in affiliated entity
3,342,436

 
1,168,911

 
(1,458,160
)
 
(376,963
)
Net loss
(7,412,487
)
 
(7,179,061
)
 
(10,717,717
)
 
(10,830,868
)
Net loss attributable to non-controlling interest
1,083

 
1,486

 
6,443

 
9,408

Net loss attributable to Inovio Pharmaceuticals, Inc.
$
(7,411,404
)
 
$
(7,177,575
)
 
$
(10,711,274
)
 
$
(10,821,460
)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders
 
 
 
 
 
 
 
Basic
$
(0.12
)
 
$
(0.12
)
 
$
(0.18
)
 
$
(0.20
)
Diluted
$
(0.12
)
 
$
(0.12
)
 
$
(0.19
)
 
$
(0.20
)
Weighted average number of common shares outstanding used in per share calculations:
 
 
 
 
 
 
 
Basic
60,610,367

 
60,392,911

 
60,232,498

 
55,159,002

Diluted
60,805,871

 
60,602,831

 
60,474,859

 
55,159,002



 
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
December 31,
2013

September 30,
2013

June 30,
2013

March 31,
2013
Consolidated Statements of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
Revenue under collaborative research and development arrangements
$
822,217

 
$
8,388,760

 
$
14,311

 
$
14,259

Revenue under collaborative research and development arrangements with affiliated entity
106,250

 
106,250

 
106,250

 
106,250

Grants and miscellaneous revenue
811,199

 
991,835

 
665,049

 
1,334,716

Total revenues
1,739,666

 
9,486,845

 
785,610

 
1,455,225

Operating Expenses:
 
 
 
 
 
 
 
Research and development
6,404,005

 
5,438,405

 
4,411,082

 
5,115,112

General and administrative
4,339,539

 
3,282,796

 
3,046,586

 
2,974,153

Gain on sale of assets
(1,000,000
)
 
—

 
(1,000,000
)
 
—

Total operating expenses
9,743,544

 
8,721,201

 
6,457,668

 
8,089,265

(Loss) Income from operations
(8,003,878
)
 
765,644

 
(5,672,058
)
 
(6,634,040
)
Interest and other income, net
8,576

 
46,787

 
37,391

 
39,460

Change in fair value of common stock warrants
(6,052,965
)
 
(34,952,210
)
 
(3,199,878
)
 
(1,427,616
)
Gain (Loss) from investment in affiliated entity
(1,419,536
)
 
3,248,926

 
(2,032,051
)
 
(836,084
)
Net loss
(15,467,803
)
 
(30,890,853
)
 
(10,866,596
)
 
(8,858,280
)
Net loss attributable to non-controlling interest
13,473

 
13,443

 
14,008

 
14,160

Net loss attributable to Inovio Pharmaceuticals, Inc.
$
(15,454,330
)
 
$
(30,877,410
)
 
$
(10,852,588
)
 
$
(8,844,120
)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders
 
 
 
 
 
 
 
          Basic
$
(0.30
)
 
$
(0.64
)
 
$
(0.24
)
 
$
(0.23
)
          Diluted
(0.30
)
 
(0.64
)
 
(0.24
)
 
(0.23
)
Weighted average number of common shares outstanding used in per share calculations:
 
 
 
 
 
 
 
          Basic
52,127,419

 
47,989,039

 
44,988,704

 
39,038,883

          Diluted
52,127,419

 
47,989,039

 
44,988,704

 
39,038,883